HRP20240082T1 - Inhibitor pde9 s okosnicom imidazopirazinona za liječenje perifernih bolesti - Google Patents

Inhibitor pde9 s okosnicom imidazopirazinona za liječenje perifernih bolesti Download PDF

Info

Publication number
HRP20240082T1
HRP20240082T1 HRP20240082TT HRP20240082T HRP20240082T1 HR P20240082 T1 HRP20240082 T1 HR P20240082T1 HR P20240082T T HRP20240082T T HR P20240082TT HR P20240082 T HRP20240082 T HR P20240082T HR P20240082 T1 HRP20240082 T1 HR P20240082T1
Authority
HR
Croatia
Prior art keywords
compound
amount
treatment
patient
administered
Prior art date
Application number
HRP20240082TT
Other languages
English (en)
Inventor
Niels Svenstrup
Kate Wen
Yazhou WANG
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of HRP20240082T1 publication Critical patent/HRP20240082T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Claims (9)

1. Oralni farmaceutski pripravak koji sadrži spoj (3S,4S)-6-(4-metil-1-pirimidin-2-ilmetil-pirolidin-3-il)-3-(tetrahidro-piran-4-il)-7H-imidazo[1,5-a]pirazin-8-on i jedan ili više farmaceutski prihvatljivih nosača, razrjeđivača, ili pomoćnih tvari, pri čemu je spoj prisutan u pripravku u količini od 0,01 mg do 1000 mg po dozi.
2. Oralni farmaceutski pripravak prema zahtjevu 1, naznačen time što je spoj prisutan u pripravku u količini od 0,05 mg do 500 mg po dozi.
3. Oralni farmaceutski pripravak prema zahtjevu 1, naznačen time što je spoj prisutan u pripravku u količini od 0,05 do 200 mg po dozi.
4. Oralni farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 3, naznačen time što se koristi u liječenju bolesti srpastih stanica.
5. Oralni farmaceutski pripravak prema zahtjevu 4 za upotrebu prema zahtjevu 4, naznačen time što se spoj daje pacijentu u jednoj do tri doze dnevno.
6. Spoj (3S,4S)-6-(4-metil-1-pirimidin-2-ilmetil-pirolidin-3-il)-3-(tetrahidropiran-4-il)-7H-imidazo[1,5-a]pirazin-8-on za upotrebu u liječenju bolesti srpastih stanica, pri čemu se spoj oralno primjenjuje pacijentu kojem je to potrebno u količini od 0,001 mg/kg do 100 mg/kg tjelesne težine dnevno.
7. Spoj za upotrebu prema zahtjevu 6, pri čemu se spoj daje pacijentu u količini od 0,01 mg/kg do 50 mg/kg tjelesne težine na dan.
8. Spoj za upotrebu prema zahtjevu 6, naznačen time što se spoj daje pacijentu u količini od 0,05 mg/kg do 10 mg/kg tjelesne težine na dan.
9. Spoj za upotrebu prema zahtjevima 6 do 8, naznačen time što se spoj daje pacijentu u jednoj do tri doze dnevno.
HRP20240082TT 2015-07-07 2016-07-06 Inhibitor pde9 s okosnicom imidazopirazinona za liječenje perifernih bolesti HRP20240082T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA201500393 2015-07-07
DKPA201500407 2015-07-10
DKPA201600209 2016-04-07
EP20217833.1A EP3865484B1 (en) 2015-07-07 2016-07-06 Pde9 inhibitor with imidazo pyrazinone backbone for treatment of peripheral diseases

Publications (1)

Publication Number Publication Date
HRP20240082T1 true HRP20240082T1 (hr) 2024-03-29

Family

ID=56345156

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20240082TT HRP20240082T1 (hr) 2015-07-07 2016-07-06 Inhibitor pde9 s okosnicom imidazopirazinona za liječenje perifernih bolesti
HRP20210543TT HRP20210543T1 (hr) 2015-07-07 2021-04-06 Inhibitori pde9 s imidazo triazinonskom okosnicom i imidazo pirazinonskom okosnicom za liječenje perifernih bolesti

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20210543TT HRP20210543T1 (hr) 2015-07-07 2021-04-06 Inhibitori pde9 s imidazo triazinonskom okosnicom i imidazo pirazinonskom okosnicom za liječenje perifernih bolesti

Country Status (21)

Country Link
US (4) US10513524B2 (hr)
EP (3) EP3865484B1 (hr)
CN (2) CN107810187B (hr)
AU (2) AU2016289856B2 (hr)
BR (1) BR112018000254A2 (hr)
CA (1) CA2990521C (hr)
DK (2) DK3303339T3 (hr)
ES (1) ES2869939T3 (hr)
FI (1) FI3865484T3 (hr)
HK (1) HK1249903A1 (hr)
HR (2) HRP20240082T1 (hr)
HU (1) HUE053968T2 (hr)
IL (2) IL280619B2 (hr)
LT (1) LT3865484T (hr)
MX (1) MX2018000283A (hr)
PL (1) PL3865484T3 (hr)
PT (1) PT3865484T (hr)
SI (1) SI3303339T1 (hr)
TN (1) TN2017000507A1 (hr)
WO (1) WO2017005786A1 (hr)
ZA (1) ZA201708341B (hr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3865484B1 (en) * 2015-07-07 2023-11-08 H. Lundbeck A/S Pde9 inhibitor with imidazo pyrazinone backbone for treatment of peripheral diseases
WO2018009424A1 (en) * 2016-07-06 2018-01-11 Imara, Inc. Pde9 inhibitors for treatment of peripheral diseases
EA201992721A1 (ru) * 2017-05-26 2020-09-10 Имара Инк. Способы получения и применения ингибиторов pde9
WO2018224455A1 (en) 2017-06-07 2018-12-13 Basf Se Substituted cyclopropyl derivatives
WO2018234488A1 (en) 2017-06-23 2018-12-27 Basf Se SUBSTITUTED CYCLOPROPYL DERIVATIVES
FI3801526T3 (fi) * 2018-05-25 2024-03-20 Cardurion Pharmaceuticals Inc 6-[(3s,4s)-4-metyyli-1-(pyrimidin-2-yylimetyyli)pyrrolidin-3-yyli]-3-tetrahydropyran-4-yyli-7h-imidatso[1,5-a]pyratsin-8-onin monohydraattimuotoja ja kiteisiä muotoja
JP2021535908A (ja) * 2018-08-31 2021-12-23 イマラ インク． 鎌状赤血球症を処置するためのｐｄｅ９阻害剤
EP3946348A4 (en) * 2019-04-05 2023-08-02 Imara Inc. PDE9 INHIBITORS FOR THE TREATMENT OF SICKLE CELL DISEASE
WO2020227399A1 (en) * 2019-05-07 2020-11-12 Imara Inc. Pde9 inhibitors for treating thalassemia
WO2022036111A1 (en) * 2020-08-13 2022-02-17 Imara Inc. Methods and compositions for treating sickle cell disease
CN112552339A (zh) * 2020-12-10 2021-03-26 安徽昊帆生物有限公司 一种o-二苯基磷酰羟胺的制备方法
TW202317579A (zh) * 2021-07-13 2023-05-01 美商傳達治療有限公司 PI3Kα抑制劑及其使用方法
CN115448864B (zh) * 2022-08-26 2023-12-22 上海方予健康医药科技有限公司 3-氟-3-（1-羟乙基）吡咯烷-1-羧酸叔丁酯的制备方法

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB587992A (en) 1944-12-11 1947-05-12 Charles William Scaife Improvements in and relating to the production of organic nitrogen compounds
US3578687A (en) 1968-01-30 1971-05-11 Texaco Inc Process for producing 4-nitroalkanoic acids
US3819561A (en) 1970-10-23 1974-06-25 Aerojet General Co Wetting agents for non-aqueous dispersions
JPS5313608B2 (hr) 1972-06-16 1978-05-11
JPS5318013B2 (hr) 1973-03-19 1978-06-13
US4599430A (en) 1981-12-21 1986-07-08 The Standard Oil Company Nitrogenation of hydrocarbons, including the production of maleimide
JPS62132804A (ja) 1985-12-05 1987-06-16 Aguro Kanesho Kk 植物生長調節剤
US5412137A (en) 1993-06-07 1995-05-02 Sandoz Ltd. Process for preparing phosphinyloxy propanaminium inner salt derivatives
BR9508554A (pt) 1994-08-08 1997-11-25 Debiopharm Sa Preparação farmaceuticamente estável de oxaliplatina
KR100463709B1 (ko) 1994-10-13 2005-08-04 위민스 앤드 칠드런스 호스피털 애드레이드 변형된불포화지방산
US5919816A (en) 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US5741211A (en) 1995-10-26 1998-04-21 Medtronic, Inc. System and method for continuous monitoring of diabetes-related blood constituents
GB9618420D0 (en) 1996-09-04 1996-10-16 Scotia Holdings Plc Fatty acid treatment
US6187747B1 (en) 1997-09-08 2001-02-13 Panacea Biotech Limited Pharmaceutical composition comprising cyclosporin
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
DE69825173T2 (de) 1997-10-30 2005-08-25 Morishita Jintan Co. Ltd. Doppelschichtige kapsel von ungesättigten fettsäuren oder deren derivate und verfahren zu deren herstellung
GB2346877B (en) 1997-11-12 2001-12-05 Bayer Ag 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
US7795246B2 (en) 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
AU5565599A (en) 1998-08-14 2000-03-06 Dante J. Marciani Chemically modified saponins and the use thereof as adjuvants
EP1144410A2 (de) 1999-01-20 2001-10-17 Arzneimittelwerk Dresden Gmbh Verwendung von imidazo[1,5-a]-pyrido[3,2-e]-pyrazinonen als arzneimittel
ATE384035T1 (de) 1999-04-01 2008-02-15 Esperion Therapeutics Inc Ether-verbindungen, zusammensetzungen und ihre verwendung
WO2001006983A2 (en) 1999-07-22 2001-02-01 Incell Corporation, Llc Fatty acids to minimize cancer therapy side effects
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
AUPQ291499A0 (en) 1999-09-17 1999-10-07 Women's And Children's Hospital Adelaide Novel nitro and sulphur containing compounds
US6346231B1 (en) 1999-10-06 2002-02-12 Joar Opheim Flavored gelatin capsule and method of manufacture
IL139455A0 (en) 1999-11-08 2001-11-25 Pfizer Compounds for the treatment of female sexual dysfunction
US20010037598A1 (en) 1999-12-14 2001-11-08 Suppes Galen J. Process for producing cetane improvers from triglycerides
WO2001060778A2 (en) 2000-02-16 2001-08-23 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
AR034120A1 (es) 2000-04-13 2004-02-04 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
AR030416A1 (es) 2000-04-13 2003-08-20 Pharmacia Corp COMPUESTO DERIVADO HALOGENADO DEL ACIDO 2-AMINO-3,4 HEPTENOICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO uTIL COMO INHIBIDOR DE LA OXIDO NITRICO SINTETASA
AR032318A1 (es) 2000-04-13 2003-11-05 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa
ES2239155T3 (es) 2000-06-28 2005-09-16 Zambon Group S.P.A. Proceso para la preparacion de nitroalquenos.
AR031129A1 (es) 2000-09-15 2003-09-10 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
ATE365037T1 (de) 2001-03-02 2007-07-15 Debiopharm Sa Verwendung eines eine oxaliplatinlösung beinhaltenden fläschchens
JP5026655B2 (ja) 2001-04-18 2012-09-12 プロメティック、バイオサイエンシーズ、インコーポレーテッド 好中球の生存及び活性化因子としての中鎖脂肪酸、グリセリド及び類似体
US7105556B2 (en) 2001-05-30 2006-09-12 Bristol-Myers Squibb Company Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
US20040176451A1 (en) 2001-06-18 2004-09-09 Tadakazu Tamai Pparg agonistic medicinal compositions
WO2003015704A2 (en) 2001-08-17 2003-02-27 University Of Pittsburgh Administration of estradiol metabolites for the treatment or prevention of obesity, metabolic syndrome, diabetes, and vascular and renal disorders
GB0123961D0 (en) 2001-10-05 2001-11-28 Astrazeneca Ab Process and intermediates
IL161155A0 (en) 2001-11-02 2004-08-31 Pfizer Prod Inc Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
HN2002000317A (es) 2001-11-02 2003-05-21 Pfizer Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
CA2465117C (en) 2001-11-06 2012-01-03 Brigham And Women's Hospital, Inc. Lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
GB2388111A (en) 2002-05-01 2003-11-05 Bayer Ag Novel imidazotriazinone compounds
US6684626B1 (en) 2002-07-30 2004-02-03 General Electric Company Aircraft gas turbine engine with control vanes for counter rotating low pressure turbines
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
US20060100278A1 (en) 2002-08-20 2006-05-11 Cooper Garth J S Dosage forms and related therapies
AU2003272738B2 (en) 2002-09-27 2010-04-01 Martek Biosciences Corporation Docosahexaenoic acid for improved glycemic control
AU2003284885A1 (en) 2002-10-21 2004-05-13 Kensey Nash Corporation Device and methods for sequential, regional delivery of multiple cytotoxic agents
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
WO2005016864A1 (en) 2003-07-29 2005-02-24 The Arizona Disease Control Research Commission Conjugated nitro alkene anticancer agents based on isoprenoid metabolism
US20050136103A1 (en) 2003-09-17 2005-06-23 Ben-Sasson Shmuel A. Compositions capable of facilitating penetration across a biological barrier
US7935365B2 (en) 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
BRPI0416118A (pt) 2003-10-31 2007-01-02 Pfizer Prod Inc inibição da fosfodiesterase 9 como tratamento para estados relacionados com a obesidade
US20090215895A1 (en) 2004-01-30 2009-08-27 Peplin Biolipids Pty Ltd Therapeutic and carrier molecules
EP1742663A2 (en) 2004-04-15 2007-01-17 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
WO2005110396A2 (en) 2004-04-28 2005-11-24 Uab Research Foundation Nitrated lipids and methods of making and using thereof
US7872095B2 (en) 2004-07-19 2011-01-18 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
MY139689A (en) 2004-07-20 2009-10-30 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
JPWO2006011397A1 (ja) 2004-07-27 2008-05-01 興和株式会社 糖尿病の予防または治療のための薬剤
AU2005306320B2 (en) 2004-11-19 2011-09-08 Martek Biosciences Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
WO2006058250A2 (en) 2004-11-24 2006-06-01 Spi Pharma, Inc. Orally disintegrating compositions
AU2011202664B2 (en) 2004-12-08 2012-04-05 Cedars-Sinai Medical Center Methods for diagnosis and treatment of Crohn's disease
US20070032420A1 (en) 2005-02-09 2007-02-08 Entelos, Inc. Treating diabetes with glucagon-like peptide-1 secretagogues
CA2620223A1 (en) 2005-09-02 2007-03-08 Abbott Laboratories Novel imidazo based heterocycles
GB0522569D0 (en) 2005-11-04 2005-12-14 Univ Bath Biocompatible drug delivery device
TW200815436A (en) 2006-05-30 2008-04-01 Elbion Ag 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
US9274129B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
US20090264483A1 (en) 2006-07-14 2009-10-22 Cedars-Sinai Medical Center METHODS OF USING PPAR-gamma AGONISTS AND CASPASE-DEPENDENT CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER
RU2009101324A (ru) 2006-07-19 2010-07-27 Ризолвикс Фармасьютикалз, Инк. (Us) Композиции и способы лечения воспаления слизистой оболочки
US7947577B2 (en) 2006-09-08 2011-05-24 Tokuyama Corporation Method and apparatus for producing group III nitride
CN101557826A (zh) * 2006-12-13 2009-10-14 Aska制药株式会社 泌尿系统疾病的治疗药
CN101553491B (zh) 2006-12-13 2013-05-29 Aska制药株式会社 喹喔啉衍生物
WO2008103753A2 (en) 2007-02-20 2008-08-28 Martek Biosciences Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
MX2009011830A (es) 2007-05-11 2009-11-13 Pfizer Compuestos amino-heterociclicos.
DE102007032349A1 (de) 2007-07-11 2009-01-15 Bayer Healthcare Ag Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
WO2009017802A1 (en) 2007-08-01 2009-02-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Nitro-fattyacid modulation of type ii diabetes
AU2008301895A1 (en) 2007-09-14 2009-03-26 Resolvyx Pharmaceuticals, Inc. Oxylipin compounds for treating autoimmune diseases
EP2271929B1 (en) 2008-04-18 2015-11-25 The University of Utah Research Foundation Use of nitrated lipids for treatment of lipid disorders and obesity, and lipid- and obesity-related conditions
DK2280928T3 (en) 2008-05-01 2018-11-05 Complexa Inc Vinyl-substituted fatty acids
WO2009149496A1 (en) 2008-06-10 2009-12-17 Central Northern Adelaide Health Service Treatment of diabetes and complications thereof and related disorders
US8686038B2 (en) 2008-06-19 2014-04-01 The Univsersity of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
JP5579715B2 (ja) 2008-07-29 2014-08-27 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ ｃｄｋ阻害剤および抗悪性腫瘍剤を含む治療用組合せ
CA2740000C (en) 2008-10-09 2017-12-12 Tekmira Pharmaceuticals Corporation Improved amino lipids and methods for the delivery of nucleic acids
WO2010078504A1 (en) 2008-12-31 2010-07-08 Nitromega Corp. Nutraceuticals containing nitro fatty acids
US8937194B2 (en) 2008-12-31 2015-01-20 Nitromega Corp. Topical compositions containing nitro fatty acids
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
US20100286272A1 (en) 2009-05-08 2010-11-11 Perricone Nicholas V Methods Of Use Of Nitroalkene Compositions In Dermatologic Applications
US20100286271A1 (en) 2009-05-08 2010-11-11 Perricone Nicholas V Nitro-alkyl Compound Compositions
US20100286257A1 (en) 2009-05-08 2010-11-11 Perricone Nicholas V Methods Of Use Of Nitroalkane Compositions In Dermatologic Applications To Prevent or Treat Skin Aging
WO2011011712A1 (en) 2009-07-24 2011-01-27 Concert Pharmaceuticals, Inc. Substituted imidazotriazines
EP2459510A4 (en) 2009-07-29 2013-08-07 Phenomenome Discoveries Inc HYDROXIDE-FATTY ACID COMPOSITIONS AND USES THEREOF FOR ILLNESS TREATMENT AND DIAGNOSIS
CA2769624C (en) 2009-07-31 2018-09-11 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Electrophilic fatty acid derivatives as anti-inflammatory agents
WO2011028820A1 (en) 2009-09-02 2011-03-10 Concert Pharmaceuticals, Inc. Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds
WO2011030351A2 (en) 2009-09-03 2011-03-17 Rubicon Research Private Limited Taste - masked pharmaceutical compositions
CA2781276A1 (en) 2009-10-02 2011-04-07 Complexa, Inc. Heteroatom containing substituted fatty acids
EP2499120A4 (en) 2009-11-09 2013-06-26 Medivir Ab NEW 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN HEMMER
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
WO2011113507A2 (en) 2010-03-15 2011-09-22 Ulrich Dietz Use of nitrocarboxylic acids for the treatment, diagnosis and prophylaxis of aggressive healing patterns
BR112012027915A2 (pt) 2010-05-13 2018-10-23 Nitromega Corp nitro-ácidos graxos - neuroproteção e/ou inibição do declínio cognitivo
WO2012006014A2 (en) 2010-06-28 2012-01-12 Complexa, Inc. Multi-component pharmaceuticals for treating diabetes
CN103313988B (zh) 2010-09-20 2016-06-08 论坛医药有限公司 咪唑并三嗪酮化合物
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
WO2013028501A1 (en) 2011-08-19 2013-02-28 The University Of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
DK2769980T3 (en) 2011-10-07 2016-04-11 Eisai R&D Man Co Ltd Pyrazolquinolinderivat as pde9 inhibitors
JP2015531401A (ja) 2011-10-10 2015-11-02 ハー・ルンドベック・アクチエゼルスカベット イミダゾピラジノン骨格を有するｐｄｅ９ｉ
US9271952B2 (en) 2011-10-11 2016-03-01 Complexa, Inc. Compositions and methods for treating nephropathy
DE102012008730A1 (de) 2011-12-02 2013-06-06 Dr. Budz GmbH Orale Zusammensetzungen mit ungesättigten C18-Fettsäuren und ihre Verwendung
CN107082783B (zh) * 2012-01-26 2019-03-22 H.隆德贝克有限公司 具有咪唑并三嗪酮骨架的pde9抑制剂
WO2013116765A1 (en) 2012-02-01 2013-08-08 City Of Hope Ribonucleotide reductase inhibitors and methods of use
CA2863765A1 (en) 2012-02-03 2013-08-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Fatty acids as anti-inflammatory agents
US10435367B2 (en) 2013-03-14 2019-10-08 City Of Hope Indirubin derivatives, and uses thereof
WO2013142269A1 (en) 2012-03-19 2013-09-26 Envivo Pharmaceuticals, Inc. Imidazotriazinone compounds
US10058688B2 (en) 2012-05-09 2018-08-28 Massachusetts Institute Of Technology Medicament, method, and drug delivery device for treatment of ovarian cancer
KR102157548B1 (ko) 2012-08-31 2020-09-18 타리스 바이오메디컬 엘엘씨 방광암의 치료를 위한 옥살리플라틴을 포함하는 약물 전달 시스템과 방법
US20140271844A1 (en) 2013-03-15 2014-09-18 Nitromega Corp. Compositions containing nitro fatty acids
WO2014169137A1 (en) 2013-04-10 2014-10-16 Massachusetts Institute Of Technology Local drug delivery devices and methods for treating cancer
CN105339006A (zh) 2013-05-10 2016-02-17 尼特罗米加公司 含有脂肪酸和亚硝酸盐的营养或膳食补充剂
US20150051283A1 (en) 2013-06-14 2015-02-19 Complexa, Inc. Composition and method for inhibition of pkng from mycobacterium tuberculosis
CN105744983B (zh) 2013-08-12 2019-12-27 纳米医学系统公司 用于缓释在增溶剂中的低水溶性治疗剂的装置和方法
WO2015073527A1 (en) 2013-11-12 2015-05-21 Complexa, Inc. Nitroalkene tocopherols and analogs thereof for use in the treatment and prevention of inflammation related conditions
WO2015185499A1 (en) 2014-06-06 2015-12-10 H. Lundbeck A/S Pde9 inhibitors with 1-benzyl-2,5,6,8-tetrahydro-3-oxo-2,7-naphthyridine-4-carbonitrile backbone
CA2961489A1 (en) 2014-09-17 2016-03-24 Glen Robert RENNIE Sgc stimulators
US20180092948A1 (en) 2015-04-02 2018-04-05 Aobiome Llc Production of nitro-fatty acids and nitro-hydrocarbons by ammonia oxidizing bacteria
EP3865484B1 (en) 2015-07-07 2023-11-08 H. Lundbeck A/S Pde9 inhibitor with imidazo pyrazinone backbone for treatment of peripheral diseases
IL297844A (en) 2015-10-02 2023-01-01 Complexa Inc Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids
CN113620950A (zh) 2016-02-19 2021-11-09 凤凰分子设计公司 可用作rsk抑制剂的羧酰胺衍生物
WO2018009424A1 (en) 2016-07-06 2018-01-11 Imara, Inc. Pde9 inhibitors for treatment of peripheral diseases
EA201992721A1 (ru) 2017-05-26 2020-09-10 Имара Инк. Способы получения и применения ингибиторов pde9
FI3801526T3 (fi) 2018-05-25 2024-03-20 Cardurion Pharmaceuticals Inc 6-[(3s,4s)-4-metyyli-1-(pyrimidin-2-yylimetyyli)pyrrolidin-3-yyli]-3-tetrahydropyran-4-yyli-7h-imidatso[1,5-a]pyratsin-8-onin monohydraattimuotoja ja kiteisiä muotoja
JP2021535908A (ja) 2018-08-31 2021-12-23 イマラ インク． 鎌状赤血球症を処置するためのｐｄｅ９阻害剤
EP3946348A4 (en) 2019-04-05 2023-08-02 Imara Inc. PDE9 INHIBITORS FOR THE TREATMENT OF SICKLE CELL DISEASE
WO2020227399A1 (en) 2019-05-07 2020-11-12 Imara Inc. Pde9 inhibitors for treating thalassemia
WO2022036111A1 (en) 2020-08-13 2022-02-17 Imara Inc. Methods and compositions for treating sickle cell disease
JP2023550269A (ja) 2020-10-27 2023-12-01 カーデュリオン・ファーマシューティカルズ・インコーポレイテッド 心不全を治療するためのｐｄｅ９阻害剤

Also Published As

Publication number Publication date
IL256143A (en) 2018-02-28
CA2990521A1 (en) 2017-01-12
EP3303339B1 (en) 2021-01-13
BR112018000254A2 (pt) 2018-09-04
AU2016289856B2 (en) 2020-11-26
AU2016289856A1 (en) 2018-01-04
IL280619B2 (en) 2023-10-01
SI3303339T1 (sl) 2021-05-31
IL280619A (en) 2021-03-25
ZA201708341B (en) 2021-05-26
US11608342B2 (en) 2023-03-21
WO2017005786A1 (en) 2017-01-12
HRP20210543T1 (hr) 2021-05-14
US20180194770A1 (en) 2018-07-12
US10513524B2 (en) 2019-12-24
HUE053968T2 (hu) 2021-08-30
EP4335497A2 (en) 2024-03-13
AU2021201227A1 (en) 2021-03-11
EP3303339A1 (en) 2018-04-11
EP4335497A3 (en) 2024-05-01
CN112010861A (zh) 2020-12-01
PT3865484T (pt) 2024-01-30
LT3865484T (lt) 2024-02-12
US20230183255A1 (en) 2023-06-15
DK3303339T3 (da) 2021-04-12
AU2021201227B2 (en) 2023-02-16
IL256143B (en) 2021-02-28
FI3865484T3 (fi) 2024-01-24
US20200062770A1 (en) 2020-02-27
CN107810187B (zh) 2020-09-15
TN2017000507A1 (en) 2019-04-12
EP3865484B1 (en) 2023-11-08
IL280619B1 (en) 2023-06-01
CA2990521C (en) 2023-10-10
PL3865484T3 (pl) 2024-04-22
DK3865484T3 (da) 2024-01-29
EP3865484A1 (en) 2021-08-18
US20210094960A1 (en) 2021-04-01
ES2869939T3 (es) 2021-10-26
CN107810187A (zh) 2018-03-16
MX2018000283A (es) 2018-11-22
HK1249903A1 (zh) 2018-11-16

Similar Documents

Publication Publication Date Title
HRP20240082T1 (hr) Inhibitor pde9 s okosnicom imidazopirazinona za liječenje perifernih bolesti
HRP20180237T4 (hr) Metode za liječenje hcv-a
ZA202303227B (en) Crystalline forms of a bruton's tyrosine kinase inhibitor
NZ751418A (en) Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
NZ605888A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain
DOP2011000343A (es) Derivados de piridina tieno [2,3-b] como inhibidores de replicacion viral
MX2012007410A (es) Compuestos antivirales novedosos.
NZ627827A (en) Antiviral combinations involving (3s, 11ar)-n-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
IL295418B1 (en) Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus
RU2015102772A (ru) Бензодиазелипы для мелкоклеточного рака легкого
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
RU2013148779A (ru) Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени
MX2019011620A (es) Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos.
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
RU2019108259A (ru) Комбинированная терапия для лечения гепатоцеллюлярной карциномы
RU2012108144A (ru) Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами
PH12014501601A1 (en) Artemisinin-based combination therapy for treating viral mediated disease
RU2015111491A (ru) Комбинация макроциклического ингибитора протеазы hcv, ненуклеозидного ингибитора hcv и ритонавира
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
RU2013129824A (ru) Новое лечение инфекции вируса гепатита с
RU2012136190A (ru) Фармацевтический состав для профилактики или лечения артрозоартрита, содержащий ребамипид в качестве активного ингредиента
MY166556A (en) Pharmaceutical formulation for topical administration comprising b220
TN2016000179A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor.
RU2014143213A (ru) Соединения ингибитора тирозинкиназы и их применение